On Jan 31, 2020, Taconic Biosciences announced that it had expanded its immuno-oncology portfolio with the launch of the new B2m-NOG mouse model. Taconic’s immuno-oncology portfolio is built on the CIEA NOG mouse, a severely immunodeficient mouse with diverse applications based on its improved ability to engraft human cells and tissues.